Yurpeak, the second brand of the blockbuster fat-loss injection tirzepatide from US pharma major Eli Lilly, has officially entered the Indian market through Cipla.

Eli Lilly launched tirzepatide earlier this year as Mounjaro, and with Yurpeak’s rollout on Wednesday, the drug is now positioned to reach deeper into India’s smaller towns and cities.

Tirzepatide, part of the Glucagon-Like Peptide-1 (GLP-1) therapy class originally designed for type 2 diabetes, mimics gut hormones to regulate blood sugar, suppress appetite and slow digestion.

These effects have turned GLP-1 drugs into some of the world’s most powerful obesity-reduction tools. India has already seen the arrival of two major players in this category—Wegovy by Novo Nordisk and Mounjaro by Eli Lilly—marking the country’s first w

See Full Page